Tìm theo
Mexiletine
Các tên gọi khác (8 ) :
  • (+-)-1-(2,6-Dimethylphenoxy)propan-2-amine
  • (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane
  • 1-(2,6-Dimethylphenoxy)-2-propanamine
  • 1-(2',6'-Dimethylphenoxy)-2-aminopropane
  • 1-Methyl-2-(2,6-xylyloxy)ethanamine
  • Mexiletina
  • Mexilétine
  • Mexiletinum
Thuốc chống loạn nhịp
Thuốc Gốc
Small Molecule
CAS: 31828-71-4
ATC: C01BB02
ĐG : Atlantic Biologicals Corporation , http://www.atlanticbiologicals.com
CTHH: C11H17NO
PTK: 179.2588
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C11H17NO
Phân tử khối
179.2588
Monoisotopic mass
179.131014171
InChI
InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3
InChI Key
InChIKey=VLPIATFUUWWMKC-UHFFFAOYSA-N
IUPAC Name
2-(2-aminopropoxy)-1,3-dimethylbenzene
Traditional IUPAC Name
mexiletine
SMILES
CC(N)COC1=C(C)C=CC=C1C
Độ tan chảy
203-205 °C
Độ hòa tan
8.25 mg/mL
logP
2.15
logS
-2.5
pKa (Strongest Basic)
9.52
PSA
35.25 Å2
Refractivity
54.97 m3·mol-1
Polarizability
21.17 Å3
Rotatable Bond Count
3
H Bond Acceptor Count
2
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
1
Bioavailability
1
Rule of Five
true
Ghose Filter
true
pKa
9.2
Dược Lực Học : Mexiletine is a local anesthetic, antiarrhythmic agent (Class Ib), structurally similar to lidocaine, but orally active. Mexiletine has fast onset and offset kinetics, meaning that they have little or no effect at slower heart rates, and more effects at faster heart rates. It shortens the action potential duration, reduces refractoriness, and decreases Vmax in partially depolarized cells with fast response action potentials. Mexiletine either does not change the action potential duration, or decreases the action potential duration.
Cơ Chế Tác Dụng : Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. [PubChem] Mexiletine, like lidocaine, inhibits the inward sodium current required for the initiation and conduction of impulses, thus reducing the rate of rise of the action potential, Phase 0. It achieves this reduced sodium current by inhibiting sodium channels. Mexiletine decreases the effective refractory period (ERP) in Purkinje fibers in the heart. The decrease in ERP is of lesser magnitude than the decrease in action potential duration (APD), which results in an increase in the ERP/APD ratio. It does not significantly affect resting membrane potential or sinus node automaticity, left ventricular function, systolic arterial blood pressure, atrioventricular (AV) conduction velocity, or QRS or QT intervals
Dược Động Học :
▧ Absorption :
Well absorbed (bioavailability 90%) from the gastrointenstinal tract.
▧ Volume of Distribution :
* 5 to 7 L/lg
▧ Protein binding :
50-60%
▧ Metabolism :
Primarily hepatic (85%) via CYP2D6 and CYP1A2 (primarily CYP2D6).
▧ Route of Elimination :
Approximately 10% is excreted unchanged by the kidney. The urinary excretion of N-methylmexiletine in man is less than 0.5%.
▧ Half Life :
10-12 hours
Độc Tính : Symptoms of overdose include nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse, and coma.
Chỉ Định : For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
Tương Tác Thuốc :
  • Aminophylline Mexiletine increases the effect and toxicity of theophylline
  • Bendamustine Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion.
  • Dyphylline Mexiletine increases the effect and toxicity of theophylline
  • Eltrombopag Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
  • Ethotoin The hydantoin decreases the effect of mexiletine
  • Etravirine Mexiletine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor mexiletine therapy for reduced effectiveness.
  • Fluvoxamine Fluvoxamine may increase the therapeutic and adverse effects of mexiletine.
  • Fosphenytoin The hydantoin decreases the effect of mexiletine
  • Mephenytoin The hydantoin decreases the effect of mexiletine
  • Oxtriphylline Mexiletine increases the effect and toxicity of theophylline
  • Phenytoin The hydantoin decreases the effect of mexiletine
  • Propafenone Propafenone may increase the effect and toxicity of mexilitine.
  • Ramelteon Mexiletine increases levels/toxicity of ramelteon
  • Rifampicin Rifampin decreases the effect of mexiletine
  • Tacrine The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Mexiletine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Mexiletine is initiated, discontinued or if the dose is changed.
  • Terbinafine Terbinafine may reduce the metabolism and clearance of Mexiletine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mexiletine if Terbinafine is initiated, discontinued or dose changed.
  • Terfenadine Increased risk of cardiotoxicity and arrhythmias
  • Theophylline Mexiletine increases the effect and toxicity of theophylline
  • Thiothixene The strong CYP1A2 inhibitor, Mexiletine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Mexiletine is initiated, discontinued or dose changed.
  • Tizanidine Mexilitene may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
  • Vilazodone Monitor for increased serum concentrations/toxic effects of mexiletine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased concentrations/effects if an SSRI is discontinued/dose decreased.
Liều Lượng & Cách Dùng : Capsule - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00379
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=4178
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505491
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07220
ChemSpider
http://www.chemspider.com/Chemical-Structure.4034.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50117271
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0597-0068-01
PharmGKB
http://www.pharmgkb.org/drug/PA450488
Wikipedia
http://en.wikipedia.org/wiki/Mexiletine
RxList
http://www.rxlist.com/cgi/generic3/mexiletine.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mex1261.shtml
Drugs.com
http://www.drugs.com/cdi/mexiletine.html
... loading
... loading